Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tranylcypromine
Drug ID BADD_D02262
Description A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Indications and Usage For the treatment of major depressive episode without melancholia.
Marketing Status approved; investigational
ATC Code N06AF04
DrugBank ID DB00752
KEGG ID D08625
MeSH ID D014191
PubChem ID 5530
TTD Drug ID D0H0HJ
NDC Product Code 0527-3010; 10135-739; 43547-655; 70954-538
UNII 3E3V44J4Z9
Synonyms Tranylcypromine | trans-2-Phenylcyclopropylamine | trans 2 Phenylcyclopropylamine | Tranylcypromine Sulfate | Sulfate, Tranylcypromine | Jatrosom | Transamine | Parnate
Chemical Information
Molecular Formula C9H11N
CAS Registry Number 155-09-9
SMILES C1C(C1N)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatitis09.01.07.004---
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperpyrexia08.05.02.002---
Hypertension24.08.02.0010.034871%
Hypertensive crisis24.08.01.0010.014137%-
Hypoaesthesia17.02.06.023; 23.03.03.081---
Hypotension24.06.03.002--
Insomnia17.15.03.002; 19.02.01.002--
Jaundice cholestatic09.01.01.005---
Leukopenia01.02.02.001---
Loss of consciousness17.02.04.004---
Morphoea10.04.07.002; 15.06.01.008; 23.03.02.011---
Muscle spasms15.05.03.004--
Mydriasis06.05.03.004; 17.02.11.003---
Myoclonus17.02.05.008---
Nausea07.01.07.0010.020734%
Oedema08.01.07.006; 14.05.06.010---
Orthostatic hypotension17.05.01.020; 24.06.03.004---
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.0940.009425%
Photophobia06.01.01.004; 17.17.02.006--
Pollakiuria20.02.02.007--
Rash23.03.13.001---
Sensory loss17.02.07.007---
Serotonin syndrome12.03.01.041; 15.05.04.016; 17.05.02.0040.037698%-
Somnolence17.02.04.006; 19.02.05.003--
Subarachnoid haemorrhage12.01.10.011; 17.08.01.010; 24.07.04.0040.009425%-
Tachycardia02.03.02.007---
Therapeutic response unexpected08.06.01.0010.009425%-
Thrombocytopenia01.08.01.002---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene